|
Before hUCB-MSC injection
|
|
Total
|
2 (66.7) [4]
|
5 (83.3) [5]
|
|
Ommaya site pain
|
0 [0]
|
2 (33.3) [2]
|
|
Procedural pain
|
1 (33.3) [1]
|
1 (16.7) [1]
|
|
Headache
|
1 (33.3) [2]
|
0 [0]
|
|
Device malfunction
|
0 [0]
|
1 (16.7) [1]
|
|
Enteritis
|
1 (33.3) [1]
|
0 [0]
|
|
Otolithiasis
|
0 [0]
|
1 (16.7) [1]
|
|
After hUCB-MSC injection
|
|
Total
|
3 (100.0) [21]
|
6 (100.0) [48]
|
|
Nervous system disorders
| | |
|
Headache
|
2 (66.7) [5]
|
5 (83.3) [12]
|
|
Paraesthesia
|
0 [0]
|
2 (33.3) [4]
|
|
Gastrointestinal disorders
| | |
|
Nausea
|
2 (66.7) [E2]
|
3 (50.0) [7]
|
|
Vomiting
|
1 (33.3) [2]
|
3 (50.0) [6]
|
|
Abdominal pain
|
0 [0]E
|
1 (16.7) [1]
|
|
Dyspepsia
|
1 (33.3) [1]
|
0 [0]
|
|
General disorders and administration site conditions
|
|
Fever
|
3 (100) [7]
|
6 (100) [13]
|
|
Chills
|
0 [0]
|
1 (16.7) [1]
|
|
Ommaya site pain
|
1 (33.3) [1]
|
0 [0]
|
|
Pain other than the Ommaya site
|
0 [0]
|
1 (16.7) [1]
|
|
Musculoskeletal and connective tissue disorders
|
|
Musculoskeletal stiffness
|
0 [0]
|
1 (16.7) [1]
|
|
Myalgia
|
1 (33.3) [2]
|
0 [0]
|
|
Arthralgia
|
0 [0]
|
1 (16.7) [1]
|
|
Periarthritis
|
0 [0]
|
1 (16.7) [1]
|
|
Infections and infestations
| | |
|
Impetigo
|
1 (33.3) [1]
|
0 [0]
|
|
Psychiatric disorders
| | |
|
Delusion
|
0 [0]
|
0 [0]
|
